757 related articles for article (PubMed ID: 22729516)
1. An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer.
Tsuji T; Nakamori M; Iwahashi M; Nakamura M; Ojima T; Iida T; Katsuda M; Hayata K; Ino Y; Todo T; Yamaue H
Int J Cancer; 2013 Jan; 132(2):485-94. PubMed ID: 22729516
[TBL] [Abstract][Full Text] [Related]
2. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
Aghi M; Rabkin SD; Martuza RL
Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Martuza RL; Rabkin SD; Kurtz A
Mol Ther; 2006 Dec; 14(6):789-97. PubMed ID: 17045531
[TBL] [Abstract][Full Text] [Related]
4. Combination of the tumor angiogenesis inhibitor bevacizumab and intratumoral oncolytic herpes virus injections as a treatment strategy for human gastric cancers.
Deguchi T; Shikano T; Kasuya H; Nawa A; Fujiwara S; Takeda S; Gewen T; Sahin TT; Yamada S; Kanzaki A; Yamamura K; Fujii T; Sugimoto H; Nomoto S; Fukuda S; Nishikawa Y; Kodera Y; Nakao A
Hepatogastroenterology; 2012 Sep; 59(118):1844-50. PubMed ID: 22172413
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic herpes simplex virus treatment of metastatic breast cancer.
Wang J; Hu P; Zeng M; Rabkin SD; Liu R
Int J Oncol; 2012 Mar; 40(3):757-63. PubMed ID: 22108767
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma.
Fu X; Nakamori M; Tao L; Amato R; Zhang X
Int J Oncol; 2007 Jun; 30(6):1561-7. PubMed ID: 17487379
[TBL] [Abstract][Full Text] [Related]
7. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft.
Tan G; Kasuya H; Sahin TT; Yamamura K; Wu Z; Koide Y; Hotta Y; Shikano T; Yamada S; Kanzaki A; Fujii T; Sugimoto H; Nomoto S; Nishikawa Y; Tanaka M; Tsurumaru N; Kuwahara T; Fukuda S; Ichinose T; Kikumori T; Takeda S; Nakao A; Kodera Y
Int J Cancer; 2015 Apr; 136(7):1718-30. PubMed ID: 25156870
[TBL] [Abstract][Full Text] [Related]
9. An oncolytic herpes simplex virus vector, G47Δ, synergizes with paclitaxel in the treatment of breast cancer.
Zeng WG; Li JJ; Hu P; Lei L; Wang JN; Liu RB
Oncol Rep; 2013 Jun; 29(6):2355-61. PubMed ID: 23525624
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic virotherapy with SOCS3 enhances viral replicative potency and oncolysis for gastric cancer.
Matsumura S; Nakamori M; Tsuji T; Kato T; Nakamura M; Ojima T; Fukuhara H; Ino Y; Todo T; Yamaue H
Oncotarget; 2021 Feb; 12(4):344-354. PubMed ID: 33659045
[TBL] [Abstract][Full Text] [Related]
11. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
12. Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus.
Dong F; Wang L; Davis JJ; Hu W; Zhang L; Guo W; Teraishi F; Ji L; Fang B
Clin Cancer Res; 2006 Sep; 12(17):5224-30. PubMed ID: 16951242
[TBL] [Abstract][Full Text] [Related]
13. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.
Thomas ED; Meza-Perez S; Bevis KS; Randall TD; Gillespie GY; Langford C; Alvarez RD
J Ovarian Res; 2016 Oct; 9(1):70. PubMed ID: 27784340
[TBL] [Abstract][Full Text] [Related]
14. Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy.
Han ZQ; Assenberg M; Liu BL; Wang YB; Simpson G; Thomas S; Coffin RS
J Gene Med; 2007 Feb; 9(2):99-106. PubMed ID: 17256802
[TBL] [Abstract][Full Text] [Related]
15. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy.
Jarnagin WR; Zager JS; Hezel M; Stanziale SF; Adusumilli PS; Gonen M; Ebright MI; Culliford A; Gusani NJ; Fong Y
Cancer Gene Ther; 2006 Mar; 13(3):326-34. PubMed ID: 16138120
[TBL] [Abstract][Full Text] [Related]
16. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models.
Terada K; Wakimoto H; Tyminski E; Chiocca EA; Saeki Y
Gene Ther; 2006 Apr; 13(8):705-14. PubMed ID: 16421599
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic Virotherapy by HSV.
Watanabe D; Goshima F
Adv Exp Med Biol; 2018; 1045():63-84. PubMed ID: 29896663
[TBL] [Abstract][Full Text] [Related]
18. Combination treatment of human pancreatic cancer xenograft models with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib and oncolytic herpes simplex virus HF10.
Yamamura K; Kasuya H; Sahin TT; Tan G; Hotta Y; Tsurumaru N; Fukuda S; Kanda M; Kobayashi D; Tanaka C; Yamada S; Nakayama G; Fujii T; Sugimoto H; Koike M; Nomoto S; Fujiwara M; Tanaka M; Kodera Y
Ann Surg Oncol; 2014 Feb; 21(2):691-8. PubMed ID: 24170435
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
Todo T
Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
[TBL] [Abstract][Full Text] [Related]
20. Advance in herpes simplex viruses for cancer therapy.
Liu S; Dai M; You L; Zhao Y
Sci China Life Sci; 2013 Apr; 56(4):298-305. PubMed ID: 23564184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
